

Antimicrobial foam dressing substitution

Silver foam dressing line substitution — DermaCare · Wound Care · requested by Jenna Kowalski, NP, Nov 25, 2025

Approved

Dec 16, 2025

Equivalent clinical performance in sample evaluation; 19% category saving. Delegated fast-track authority.

Committee record: 3 for · 0 against · 0 abstentions

PROBLEM ADDRESSED

Incumbent silver foam line repriced +18% at renewal; equivalent products available at lower cost with better conformability feedback.

EVIDENCE BASIS

Sample evaluation on file.

STANDARD REPLACED OR AUGMENTED

Incumbent silver foam dressing line.

VALUE PROFILE AT DECISION

Clinical impact	2/5 · w30%
Safety	2/5 · w25%
Financial materiality	3/5 · w20%
Workflow disruption	1/5 · w15%
Organizational risk	1/5 · w10%
Net annual impact: +\$14K/yr (assumptions on case file)	

VALUE CONTRACT

Frozen Dec 16, 2025 · reviews at 90 days · immutable

WE APPROVED THIS TECHNOLOGY EXPECTING

	BASELINE	EXPECTED
Cost per treated wound	\$18.4	max \$15.1
Dressing-related irritation reports	6 /mo	max 4 /mo
Clinician adoption	0 %	min 85 %

VALUE REALIZATION TO DATE

90-day review — Value Realization Index 95% — Continue (Apr 6, 2026)

METRIC	EXPECTED	ACTUAL
Cost per treated wound	\$15.1	\$15.6
Dressing-related irritation reports	4 /mo	3 /mo
Clinician adoption	85 %	88 %

Sarah Okafor

Director, Value Analysis

Alan Chen

VP, Supply Chain & Facilities